Edwards Lifesciences

Edwards prioritizes organic investment (R&D ~18 percent of sales) and targeted M&A to extend its structural‑heart footprint. It completed the sale of Critical Care to BD for $4.2 billion, sharpening focus and adding balance sheet flexibility. Repurchases totaled ~$0.9 billion in 2025, with expanded authorization.

The attempted JenaValve acquisition was blocked by the FTC, illustrating antitrust limits to pipeline consolidation. The completed Endotronix deal adds a PMA‑approved HF platform with CED coverage tailwinds but requires measured commercialization to prove returns.

Net, capital deployment has been disciplined, with one high‑profile setback tempered by a strong core and liquidity.